Currently holds positions in Syndax Pharmaceuticals Inc, Arvinas Inc and NextCure Inc
Position | Company | Period |
---|---|---|
Chief Executive Officer, Director | Syndax Pharmaceuticals Inc | July 1, 2015 - |
Independent Director | Arvinas Inc | June 1, 2018 - |
Independent Director | NextCure Inc | April 1, 2019 - |
Executive Vice President - Global Medicines Development | AstraZeneca PLC | Jan. 1, 2013 - Sept. 15, 2015 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2023-08-10 | 2023-08-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
52,855
-74.8%
18.27965,402 USD |
52,855 -74.8% | 18.27 | 965,402 USD | |
2023-06-09 | 2023-06-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
28,273
-61.3%
21.18598,797 USD |
28,273 -61.3% | 21.18 | 598,797 USD | |
2023-06-09 | 2023-06-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
24,582
-34.8%
21.18520,625 USD |
24,582 -34.8% | 21.18 | 520,625 USD | |
2023-05-10 | 2023-05-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
52,855
-74.8%
21.411,131,478 USD |
52,855 -74.8% | 21.41 | 1,131,478 USD | |
2023-04-12 | 2023-04-10 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
52,855
-74.8%
19.531,032,237 USD |
52,855 -74.8% | 19.53 | 1,032,237 USD | |
2023-03-14 | 2023-03-13 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
52,854
-74.8%
22.531,190,674 USD |
52,854 -74.8% | 22.53 | 1,190,674 USD | |
2023-02-08 | 2023-02-06 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
52,854
-74.8%
26.831,417,909 USD |
52,854 -74.8% | 26.83 | 1,417,909 USD | |
2022-09-21 | 2022-09-20 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
59,649
-77.0%
23.251,387,012 USD |
59,649 -77.0% | 23.25 | 1,387,012 USD | |
2022-09-21 | 2022-09-19 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
114,339
-86.5%
23.032,633,044 USD |
114,339 -86.5% | 23.03 | 2,633,044 USD | |
2022-09-16 | 2022-09-16 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
53,034
-74.8%
23.221,231,423 USD |
53,034 -74.8% | 23.22 | 1,231,423 USD | |
2022-09-16 | 2022-09-16 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
71,966
-80.1%
23.221,671,015 USD |
71,966 -80.1% | 23.22 | 1,671,015 USD | |
2022-09-16 | 2022-09-15 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
66,775
-78.9%
24.201,616,035 USD |
66,775 -78.9% | 24.20 | 1,616,035 USD | |
2022-09-16 | 2022-09-14 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
87,645
-83.1%
23.802,085,855 USD |
87,645 -83.1% | 23.80 | 2,085,855 USD | |
2022-07-05 | 2022-07-01 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
62,292
-77.7%
19.001,183,430 USD |
62,292 -77.7% | 19.00 | 1,183,430 USD | |
2022-04-18 | 2022-04-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
10,754
-35.0%
67.03720,888 USD |
10,754 -35.0% | 67.03 | 720,888 USD | |
2022-04-18 | 2022-04-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
7,104
-18.8%
66.07469,356 USD |
7,104 -18.8% | 66.07 | 469,356 USD | |
2022-04-18 | 2022-04-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
3,102
-7.6%
65.24202,372 USD |
3,102 -7.6% | 65.24 | 202,372 USD | |
2022-04-05 | 2022-04-04 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
3,128
-14.9%
18.2957,220 USD |
3,128 -14.9% | 18.29 | 57,220 USD | |
2022-04-05 | 2022-04-01 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
70,545
-79.8%
17.461,231,568 USD |
70,545 -79.8% | 17.46 | 1,231,568 USD | |
2022-04-05 | 2022-04-01 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
24,500
-57.9%
17.44427,314 USD |
24,500 -57.9% | 17.44 | 427,314 USD | |
2022-04-05 | 2022-04-01 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
6,000
-12.4%
17.44104,633 USD |
6,000 -12.4% | 17.44 | 104,633 USD | |
2022-01-19 | 2022-01-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
2,108
-7.8%
67.69142,696 USD |
2,108 -7.8% | 67.69 | 142,696 USD | |
2022-01-19 | 2022-01-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
5,100
-16.0%
67.28343,144 USD |
5,100 -16.0% | 67.28 | 343,144 USD | |
2022-01-19 | 2022-01-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
3,833
-10.7%
65.24250,071 USD |
3,833 -10.7% | 65.24 | 250,071 USD | |
2022-01-19 | 2022-01-14 |
Arvinas Inc
(ARVN)
|
PS Planned sale |
9,919
-21.7%
64.33638,109 USD |
9,919 -21.7% | 64.33 | 638,109 USD | |
2021-12-20 | 2021-12-17 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
35,156
-42.1%
20.00703,120 USD |
35,156 -42.1% | 20.00 | 703,120 USD | |
2021-02-17 | 2021-02-17 |
Codiak BioSciences, Inc.
(CDAK)
|
B Purchase |
4,761
+inf%
21.0099,981 USD |
4,761 +inf% | 21.00 | 99,981 USD | |
2021-02-10 | 2021-02-08 |
Syndax Pharmaceuticals Inc
(SNDX)
|
PS Planned sale |
35,156
-42.1%
20.55722,403 USD |
35,156 -42.1% | 20.55 | 722,403 USD | |
2020-11-12 | 2020-11-10 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
17,466
-27.3%
20.06350,312 USD |
17,466 -27.3% | 20.06 | 350,312 USD | |
2020-11-12 | 2020-11-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
S Sale |
62,938
-57.5%
20.041,261,265 USD |
62,938 -57.5% | 20.04 | 1,261,265 USD | |
2020-06-25 | 2020-06-23 |
Repare Therapeutics Inc
(RPTX)
|
B Purchase |
4,800
+inf%
20.0096,000 USD |
4,800 +inf% | 20.00 | 96,000 USD | |
2020-03-25 | 2020-03-24 |
Arvinas Inc
(ARVN)
|
B Purchase |
2,500
+9.3%
38.1895,450 USD |
2,500 +9.3% | 38.18 | 95,450 USD | |
2020-02-05 | 2020-02-04 |
Syndax Pharmaceuticals Inc
(SNDX)
|
B Purchase |
12,500
+39.8%
8.00100,000 USD |
12,500 +39.8% | 8.00 | 100,000 USD | |
2019-10-11 | 2019-10-10 |
Syndax Pharmaceuticals Inc
(SNDX)
|
B Purchase |
11,000
+53.9%
5.4059,400 USD |
11,000 +53.9% | 5.40 | 59,400 USD | |
2019-05-13 | 2019-05-13 |
Syndax Pharmaceuticals Inc
(SNDX)
|
B Purchase |
7,200
+54.5%
7.2952,517 USD |
7,200 +54.5% | 7.29 | 52,517 USD | |
2019-05-13 | 2019-05-09 |
Syndax Pharmaceuticals Inc
(SNDX)
|
B Purchase |
13,200
+inf%
7.5699,726 USD |
13,200 +inf% | 7.56 | 99,726 USD |